赛升药业：10月22日召开董事会会议

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical held its 10th meeting of the 5th Board of Directors on October 22, 2025, where the proposal for the "2025 Q3 Report" was approved [1] - For the year 2024, the revenue composition of Sai Sheng Pharmaceutical is 99.63% from the pharmaceutical manufacturing industry and 0.37% from other businesses [1] - As of the time of reporting, the market capitalization of Sai Sheng Pharmaceutical is 5.8 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year [1] - There is a discussion on the hot secondary market for biopharmaceuticals, while the primary market is facing challenges in fundraising [1]